BillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™, the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy test, Northstar, that combines treatment selection with monitoring. To date, over 500,000 patients have benefited from our innovative and precise diagnostic tests, and our Annual Recurring Revenue (ARR) has grown from $0 to $125 million in the last ~4 years.
BillionToOne has successfully raised close to $400 million in funding, with a notable $130 million Series D round completed in June 2024, resulting in a company valuation of over $1 billion. This funding has come from prestigious global institutional investors, including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest. BillionToOne has recently been recognized by Forbes as one of America's Best Startup Employers for 2024, highlighting the company's exceptional work environment and commitment to innovation.
Our team has grown significantly and we now proudly employ over 400 highly skilled individuals. Despite substantial growth, we have successfully maintained the unique culture that has defined BillionToOne from inception, continuing to cultivate a team that is not only diverse and passionate but also innovative. Headquartered in Menlo Park, California, with an additional facility in Union City, California, BillionToOne remains at the forefront of significant advances in molecular diagnostics, evidenced by the recent announcement of clinical outcomes data for its Unity Fetal Risk Screen and new advancements in cancer diagnostics. For more detailed information about BillionToOne and its groundbreaking work, please visit our website at www.billiontoone.com.
Are you ready to lead a game-changing product line that’s transforming the future of prenatal care? BillionToOne is looking for a passionate and driven Senior Product Manager to lead the UNITY Fetal Risk Screen product line. In this impactful role, you’ll collaborate with world-class teams across R&D, medical, engineering, among many other functions to deliver first-and-only prenatal testing. This position reports directly to the Director of Product, Prenatal.
This position requires local candidates who are able to come to the office (Menlo Park or Union City location) at least 3 days/week. Remote candidates will not be considered.
Key Responsibilities:
- End-to-end ownership of UNITY Fetal Risk Screen: Take full ownership of the product lifecycle—from early concept development to continuous improvement.
- Drive Product Roadmap Execution: Plan, manage, and execute the product roadmap with a focus on timely delivery and strategic alignment with company goals.
- Champion Continuous Improvement: Monitor user feedback, behaviors, and market trends to uncover opportunities for enhancements.
- Leverage Data for Strategic Decision Making: Analyze key metrics to make data-informed decisions and refine product offerings.
- Be the Voice of our Customers: Deeply understand the needs of patients and obstetric providers, becoming the company’s authority on their challenges, desires, and the market landscape.
- Lead Program Execution: Mobilize cross-functional teams, to achieve ambitious product milestones and deliver exceptional results.
Requirements:
- 3–5 years of experience in product management (clinical products such as medical devices or molecular diagnostics) or product marketing in molecular diagnostics.
- A proven track record of launching clinical products for provider audiences.
- Strong insight generation skills, with experience conducting market research and gathering user feedback.
- Demonstrated ability to lead large cross-functional teams through complex product launches.
- Hybrid role requirements: Onsite 3 days/week. Fully remote candidates will not be considered.
Nice-To-Haves:
- Prior experience in women’s health is a significant plus for this role.
- An advanced/graduate degree in a biology-related discipline.
- An MBA is a plus.
Benefits And Perks:
- Working with a team of ‘rockstars’ who bring out the best in everyone
- Open, transparent culture that includes weekly Town Hall meetings
- The ability to indirectly or directly change the lives of hundreds of thousand patients
- Multiple medical benefit options; employee premiums paid 100% of select plans, dependents covered at 80%
- Extremely generous Family Bonding Leave for new parents (16 weeks, paid at 100%)
- Retirement savings program including a 4% Company match
- Free daily on-site lunches provided from top eateries
- Latest and greatest hardware (laptop, lab equipment, facilities)
- A variety of perks on campus (state of the art gym, restaurant)
- Free on-site EV charging (compatible with all EVs, including Tesla)
At BillionToOne, we are proud to offer a combination of a (1) base pay range (actual amount offered is based on experience and salary/equity options split that the candidate chooses), (2) generous equity options offering, (3) corporate bonus program, on top of (4) industry leading company benefits (free healthcare options, 401k match, very generous fully paid parental leave, etc.).
For this position, we offer a total compensation package of $250,000 per year, including a base pay range of $153,000 - $178,500 per year.
BillionToOne is an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
What We Do
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending molecular counter platform is the only technology platform that can accurately count the DNA molecules at the single-count level.
